India, Nov. 12 -- Generate Biomedicines, Inc. (GENB), a clinical-stage generative biology company, reported financial results for the third quarter ended September 30, 2026, highlighting continued clinical progress across its pipeline, new strategic collaborations, and a cash position of $404.2 million.
Generate Biomedicines develops protein-based therapeutics using artificial intelligence, machine learning, biological engineering, and large-scale experimentation. Its lead candidate, GB-0895, is an investigational anti-TSLP monoclonal antibody designed for twice-yearly dosing and is being evaluated in Phase 3 trials for severe asthma.
Third Quarter 2026 Results
The company reported revenue of $4.2 million, compared with $9.6 million in t...